Key result
NOACs reduce stroke and major bleeding versus warfarin in AF patients with diabetes.
Why the study?
Do non-vitamin K oral anticoagulants improve efficacy and safety compared to warfarin in people with atrial fibrillation and diabetes mellitus?
Population
People with both atrial fibrillation and diabetes mellitus
Comparison
Non-vitamin K oral anticoagulants (NOACs) vs Warfarin
Design
Review
Authors
Loading...
Supports NOAC preference in AF with diabetes; extends RCT data but leaves open dedicated prospective confirmation.
Do non-vitamin K oral anticoagulants improve efficacy and safety compared to warfarin in people with atrial fibrillation and diabetes mellitus?
The efficacy and safety benefits of NOACs over warfarin in atrial fibrillation extend to patients with concurrent diabetes mellitus.
Zadok et al. (2018) conducted a review in Atrial fibrillation and diabetes mellitus. Non-vitamin K oral anticoagulants vs. Warfarin was evaluated on Stroke, systemic embolism, and major bleeding. Non-vitamin K oral anticoagulants decreased the risk of stroke and systemic embolism and reduced major bleeding compared with warfarin in patients with atrial fibrillation and diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: